Immunogenicity and Biodistribution of Anthrax DNA Vaccine Delivered by Intradermal Electroporation.


Journal

Current drug delivery
ISSN: 1875-5704
Titre abrégé: Curr Drug Deliv
Pays: United Arab Emirates
ID NLM: 101208455

Informations de publication

Date de publication:
2020
Historique:
received: 16 10 2019
revised: 17 02 2020
accepted: 07 03 2020
pubmed: 15 4 2020
medline: 5 6 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

Anthrax is a lethal bacterial disease caused by gram-positive bacterium Bacillus anthracis and vaccination is a desirable method to prevent anthrax infections. In the present study, DNA vaccine encoding a protective antigen of Bacillus anthracis was prepared and we investigated the influence of DNA electrotransfer in the skin on the induced immune response and biodistribution. The tdTomato reporter gene for the whole animal in vivo imaging was used to assess gene transfer efficiency into the skin as a function of electrical parameters. Compared to that with 25 V, the transgene expression of red fluorescent protein increased significantly when a voltage of 90 V was used. Delivery of DNA vaccines expressing Bacillus anthracis protective antigen domain 4 (PAD4) with an applied voltage of 90 V induced robust PA-D4-specific antibody responses. In addition, the in vivo fate of anthrax DNA vaccine was studied after intradermal administration into the mouse. DNA plasmids remained at the skin injection site for an appropriate period of time after immunization. Intradermal administration of DNA vaccine resulted in detection in various organs (viz., lung, heart, kidney, spleen, brain, and liver), although the levels were significantly reduced. Our results offer important insights into how anthrax DNA vaccine delivery by intradermal electroporation affects the immune response and biodistribution of DNA vaccine. Therefore, it may provide valuable information for the development of effective DNA vaccines against anthrax infection.

Identifiants

pubmed: 32286944
pii: CDD-EPUB-105804
doi: 10.2174/1567201817666200414144550
doi:

Substances chimiques

Anthrax Vaccines 0
Antibodies, Bacterial 0
Antigens, Bacterial 0
Bacterial Toxins 0
Immunoglobulin G 0
Luminescent Proteins 0
Vaccines, DNA 0
anthrax toxin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

414-421

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Na Young Kim (NY)

ABION Inc., R&D Center, Seoul, Korea.

Won Rak Son (WR)

ABION Inc., R&D Center, Seoul, Korea.

Jun Young Choi (JY)

ABION Inc., R&D Center, Seoul, Korea.

Chi Ho Yu (CH)

The 4th R & D Institute Directorate, Agency for Defense Development, Daejon, Korea.

Gyeung Haeng Hur (GH)

The 4th R & D Institute Directorate, Agency for Defense Development, Daejon, Korea.

Seong Tae Jeong (ST)

The 4th R & D Institute Directorate, Agency for Defense Development, Daejon, Korea.

Young Kee Shin (YK)

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea.

Sung Youl Hong (SY)

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea.

Sungho Shin (S)

Bio-MAX/N-Bio, Seoul National University, Seoul, Korea.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH